Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director | December 12, 2025 | December 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RELMADA THERAPEUTICS, INC.
Report date December 12, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12 | Direct | 164,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 164,000 · Balance 164,000 F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2025 Filed Dec 16, 2025 14:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Appreciation Rights · Derivative | 164,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001213900-25-121971 · ownership.xml · derivative · entry 1 Fedeli Fabiana · CIK 0001961902 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2035-12-12 F1 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 23:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-25-059865 · ownership.xml · derivative · entry 1 Fedeli Fabiana · CIK 0001961902 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025. Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherStock Option (right to buy) · Derivative | 20,976 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047635 · ownership.xml · derivative · entry 2 Fedeli Fabiana · CIK 0001961902 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,522 Underlying: Common Stock · 20,976 shares Expires 2033-12-15 F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer. Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:24 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 20,976 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047635 · ownership.xml · derivative · entry 1 Fedeli Fabiana · CIK 0001961902 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,498 Underlying: Common Stock · 20,976 shares Expires 2033-12-15 F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 20,976 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:27 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 31,522 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-23-097027 · ownership.xml · derivative · entry 1 Fedeli Fabiana · CIK 0001961902 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,522 Underlying: Common Stock · 31,522 shares Expires 2033-12-15 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 15, 2024. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:06 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001213900-23-044083 · ownership.xml · derivative · entry 1 Fedeli Fabiana · CIK 0001961902 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-01-12 F1 · date: The option grant was approved by the Board of Directors of the Company on January 12, 2023, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: 25% of the option vests on the first anniversary of the date grant and the remaining 75% in equal increments of 6.25% of the total options at the end of each three-month interval over the following three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.